Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • H 89 2HCl: Potent and Selective Protein Kinase A Inhibito...

    2025-10-28

    H 89 2HCl: Potent and Selective Protein Kinase A Inhibitor for Precision cAMP/PKA Pathway Modulation

    Executive Summary: H 89 2HCl is a chemically defined, cell-permeable inhibitor of protein kinase A (PKA) with a Ki of 48 nM in cell-free assays, exhibiting over 10-fold selectivity for PKA versus PKG and over 500-fold selectivity over PKC and other kinases (ApexBio). It blocks cAMP-dependent protein phosphorylation without altering intracellular cAMP levels in PC12D cells, providing a tool for dissecting cAMP/PKA-specific functions (Wang et al., 2021). H 89 2HCl is insoluble in water and ethanol but dissolves at ≥51.9 mg/mL in DMSO, with optimal storage as a solid at -20°C. Its defined selectivity and mechanism-of-action enable precise interrogation of PKA-regulated pathways in neurodegeneration, bone remodeling, and cancer research. The compound’s rigorous performance benchmarks distinguish it from less selective kinase inhibitors, enhancing reproducibility and translational impact.

    Biological Rationale

    Protein kinase A (PKA) is a central regulator of intracellular signaling, controlling diverse processes such as cell growth, differentiation, apoptosis, and metabolism. PKA is activated by cyclic adenosine monophosphate (cAMP), a second messenger produced by adenylate cyclase in response to extracellular signals. The cAMP/PKA pathway is implicated in neurodegenerative diseases, bone remodeling, and cancer progression (Wang et al., 2021). Dysregulation of PKA signaling can alter neuronal outgrowth, osteoclast differentiation, and tumorigenic signaling. Selective inhibition of PKA enables researchers to dissect the specific contributions of this kinase in complex cellular networks. H 89 2HCl, also known as (E)-N-(2-((3-(4-bromophenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide dihydrochloride, is a gold-standard tool for this purpose (Strategic Modulation...). Its application extends to translational models, facilitating mechanistic studies in fields ranging from neuroscience to osteoimmunology and oncology.

    Mechanism of Action of H 89 2HCl

    H 89 2HCl competitively inhibits the ATP-binding site of protein kinase A (PKA) catalytic subunits. Its inhibition constant (Ki) for PKA is 48 nM in cell-free kinase assays, indicating high potency (ApexBio). The compound exhibits approximately 10-fold selectivity for PKA over protein kinase G (PKG), and over 500-fold selectivity compared to kinases such as protein kinase C (PKC), myosin light chain kinase (MLCK), calmodulin kinase II, and casein kinase I/II. Mechanistically, H 89 2HCl blocks cAMP-dependent phosphorylation events, such as histone IIb phosphorylation and neurite outgrowth in PC12D cells, without affecting basal or forskolin-stimulated cAMP production. In animal models, H 89 2HCl modulates PKA-dependent protein phosphorylation without altering upstream cAMP levels. It also inhibits other kinases (e.g., S6K1, MSK1, ROCKII, PKBα, MAPKAP-K1b) at higher concentrations, with IC50 values ranging from 80 nM to 2800 nM. The compound’s selectivity profile enables precise dissection of cAMP/PKA signaling while minimizing off-target effects when used at recommended concentrations.

    Evidence & Benchmarks

    • H 89 2HCl inhibits PKA with a Ki of 48 nM in cell-free assays (ApexBio).
    • It displays 10-fold selectivity for PKA over PKG and >500-fold selectivity over PKC, MLCK, calmodulin kinase II, and casein kinase I/II (ApexBio).
    • H 89 2HCl does not affect intracellular cAMP levels, ensuring specificity for downstream PKA events (Wang et al., 2021).
    • In PC12D cells, H 89 2HCl dose-dependently inhibits forskolin-induced neurite outgrowth and histone IIb phosphorylation (ApexBio).
    • In bone biology models, inhibition of PKA with H 89 2HCl reverses dopamine-mediated suppression of osteoclast differentiation, confirming the pathway’s regulatory role (Wang et al., 2021).
    • H 89 2HCl is insoluble in water and ethanol but soluble at ≥51.9 mg/mL in DMSO; recommended storage is as a solid at -20°C (ApexBio).

    Applications, Limits & Misconceptions

    H 89 2HCl is widely used in translational research to dissect cAMP/PKA signaling in neurodegenerative disease models, bone remodeling, and cancer biology (Strategic Modulation of cAMP/PKA Signaling...). It enables functional analysis of PKA-dependent processes, including neuronal differentiation, synaptic plasticity, osteoclastogenesis, and proliferation control. Compared to pan-kinase inhibitors, H 89 2HCl offers greater specificity, reducing confounding effects from off-target kinase inhibition. Its rigorous performance parameters facilitate reproducible mechanistic studies in cell-based and animal models. This article extends previous summaries (e.g., Potent PKA Inhibitor for Precision Signaling Studies) by integrating new data on pathway specificity and translational benchmarks.

    Common Pitfalls or Misconceptions

    • H 89 2HCl is not selective for PKA at high concentrations (>10 μM), where off-target kinase inhibition may occur (ApexBio).
    • It does not inhibit cAMP production or adenylate cyclase; its action is downstream of cAMP (Wang et al., 2021).
    • It is not suitable for in vivo diagnostic or therapeutic use; for research only (ApexBio).
    • Solubility limitations preclude use in aqueous or ethanol-based systems without DMSO (ApexBio).
    • Improper storage (e.g., in solution at room temperature) leads to degradation and loss of activity (ApexBio).

    Workflow Integration & Parameters

    H 89 2HCl is typically prepared as a stock solution in DMSO (≥51.9 mg/mL). Working concentrations between 0.1–10 μM are recommended for cell-based assays, with higher concentrations increasing the likelihood of off-target effects. The compound should be stored as a solid at -20°C; solutions should be freshly prepared and used promptly to minimize degradation. For cAMP/PKA pathway analysis, H 89 2HCl is applied prior to or concurrently with activators such as forskolin (adenylate cyclase activator) or cAMP analogs. Downstream effects are quantified via western blotting for phospho-PKA substrates, neurite outgrowth assays, or functional readouts in disease models. For example, in osteoclastogenesis studies, H 89 2HCl can confirm PKA’s role in mediating CREB phosphorylation and differentiation events (Wang et al., 2021). This workflow is detailed further in "Strategically Dissecting cAMP/PKA Signaling in Translational Research," which this article updates by incorporating new benchmarks on kinase selectivity (Strategically Dissecting...).

    Conclusion & Outlook

    H 89 2HCl (B2190) is a robust, selective inhibitor for dissecting PKA-dependent signaling with high precision. Its well-characterized mechanism and performance benchmarks support rigorous investigation of cAMP/PKA pathway roles in neuronal, skeletal, and tumor biology. Proper use—including attention to solubility, concentration, and storage—ensures maximal specificity and reproducibility. As research advances in neurodegeneration, bone remodeling, and translational disease models, H 89 2HCl remains the gold standard for precision kinase inhibition. For detailed specifications and ordering, see the H 89 2HCl product page.